Cargando…

Shenfu Injection Promotes Vasodilation by Enhancing eNOS Activity Through the PI3K/Akt Signaling Pathway In Vitro

Vasomotor dysfunction is one of the key pathological aspects of shock and heart failure (HF). Shenfu injection (SFI) has been widely used for the treatment of shock and HF in China. Pharmacological studies have suggested that SFI can reduce peripheral circulation resistance and improve microcirculat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jinqiang, Song, Wanshan, Xu, Shixin, Ma, Yan, Wei, Baoyu, Wang, Hongwu, Hua, Shengyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054240/
https://www.ncbi.nlm.nih.gov/pubmed/32161546
http://dx.doi.org/10.3389/fphar.2020.00121
_version_ 1783503152521150464
author Zhu, Jinqiang
Song, Wanshan
Xu, Shixin
Ma, Yan
Wei, Baoyu
Wang, Hongwu
Hua, Shengyu
author_facet Zhu, Jinqiang
Song, Wanshan
Xu, Shixin
Ma, Yan
Wei, Baoyu
Wang, Hongwu
Hua, Shengyu
author_sort Zhu, Jinqiang
collection PubMed
description Vasomotor dysfunction is one of the key pathological aspects of shock and heart failure (HF). Shenfu injection (SFI) has been widely used for the treatment of shock and HF in China. Pharmacological studies have suggested that SFI can reduce peripheral circulation resistance and improve microcirculation. However, whether it has a regulatory effect on macrovascular has not been elucidated. In this study, we used thoracic aorta rings isolated from Wistar rats and the human umbilical vein cell line (EA.hy926) to explore the vasodilative activity of SFI and its potential mechanisms. The relaxation due to SFI was measured after pre-treatment with selective soluble guanylate cyclase (sGC) inhibitor or cyclooxygenase (COX) inhibitor and compared with the vasodilation effect of SFI only treated with norepinephrine (NE). The contents of NO, endothelin-1 (ET-1), endothelial nitric oxide synthase (eNOS), COX-1, 6-K-PGF(1α), and caveolin-1 were evaluated respectively. Additionally, the level of eNOS mRNA and total eNOS and its phosphorylation were studied to investigate the potential mechanisms involved. Experimental results showed that SFI markedly attenuated NE-induced vasoconstriction but that this effect was significantly eliminated after pre-incubation with the selective sGC inhibitor 1-H-[1, 2, 4] oxadiazolo [4, 3-α] quinoxaline-1-one (ODQ), instead of the COX inhibitor indomethacin (INDO). SFI significantly increased the eNOS content and up-regulated the eNOS mRNA expression, while it did not affect the content of COX-1 and 6-K-PGF(1α). SFI also markedly increased NO content but significantly reduced the content of ET-1 and caveolin-1 in the cell supernatant. Furthermore, it promoted the expression of total eNOS and the phosphorylation of eNOS at serine (Ser) 1177 but inhibited the phosphorylation at threonine (Thr) 495, which was significantly reversed by PI3K-specific inhibitor LY294002. In conclusion, our study showed the vasodilation effect of SFI in thoracic aorta is mediated entirely by enhancing eNOS activity through the PI3K/Akt signaling pathway, providing novel knowledge on the effect of SFI on shock and HF for future clinical applications.
format Online
Article
Text
id pubmed-7054240
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70542402020-03-11 Shenfu Injection Promotes Vasodilation by Enhancing eNOS Activity Through the PI3K/Akt Signaling Pathway In Vitro Zhu, Jinqiang Song, Wanshan Xu, Shixin Ma, Yan Wei, Baoyu Wang, Hongwu Hua, Shengyu Front Pharmacol Pharmacology Vasomotor dysfunction is one of the key pathological aspects of shock and heart failure (HF). Shenfu injection (SFI) has been widely used for the treatment of shock and HF in China. Pharmacological studies have suggested that SFI can reduce peripheral circulation resistance and improve microcirculation. However, whether it has a regulatory effect on macrovascular has not been elucidated. In this study, we used thoracic aorta rings isolated from Wistar rats and the human umbilical vein cell line (EA.hy926) to explore the vasodilative activity of SFI and its potential mechanisms. The relaxation due to SFI was measured after pre-treatment with selective soluble guanylate cyclase (sGC) inhibitor or cyclooxygenase (COX) inhibitor and compared with the vasodilation effect of SFI only treated with norepinephrine (NE). The contents of NO, endothelin-1 (ET-1), endothelial nitric oxide synthase (eNOS), COX-1, 6-K-PGF(1α), and caveolin-1 were evaluated respectively. Additionally, the level of eNOS mRNA and total eNOS and its phosphorylation were studied to investigate the potential mechanisms involved. Experimental results showed that SFI markedly attenuated NE-induced vasoconstriction but that this effect was significantly eliminated after pre-incubation with the selective sGC inhibitor 1-H-[1, 2, 4] oxadiazolo [4, 3-α] quinoxaline-1-one (ODQ), instead of the COX inhibitor indomethacin (INDO). SFI significantly increased the eNOS content and up-regulated the eNOS mRNA expression, while it did not affect the content of COX-1 and 6-K-PGF(1α). SFI also markedly increased NO content but significantly reduced the content of ET-1 and caveolin-1 in the cell supernatant. Furthermore, it promoted the expression of total eNOS and the phosphorylation of eNOS at serine (Ser) 1177 but inhibited the phosphorylation at threonine (Thr) 495, which was significantly reversed by PI3K-specific inhibitor LY294002. In conclusion, our study showed the vasodilation effect of SFI in thoracic aorta is mediated entirely by enhancing eNOS activity through the PI3K/Akt signaling pathway, providing novel knowledge on the effect of SFI on shock and HF for future clinical applications. Frontiers Media S.A. 2020-02-26 /pmc/articles/PMC7054240/ /pubmed/32161546 http://dx.doi.org/10.3389/fphar.2020.00121 Text en Copyright © 2020 Zhu, Song, Xu, Ma, Wei, Wang and Hua http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhu, Jinqiang
Song, Wanshan
Xu, Shixin
Ma, Yan
Wei, Baoyu
Wang, Hongwu
Hua, Shengyu
Shenfu Injection Promotes Vasodilation by Enhancing eNOS Activity Through the PI3K/Akt Signaling Pathway In Vitro
title Shenfu Injection Promotes Vasodilation by Enhancing eNOS Activity Through the PI3K/Akt Signaling Pathway In Vitro
title_full Shenfu Injection Promotes Vasodilation by Enhancing eNOS Activity Through the PI3K/Akt Signaling Pathway In Vitro
title_fullStr Shenfu Injection Promotes Vasodilation by Enhancing eNOS Activity Through the PI3K/Akt Signaling Pathway In Vitro
title_full_unstemmed Shenfu Injection Promotes Vasodilation by Enhancing eNOS Activity Through the PI3K/Akt Signaling Pathway In Vitro
title_short Shenfu Injection Promotes Vasodilation by Enhancing eNOS Activity Through the PI3K/Akt Signaling Pathway In Vitro
title_sort shenfu injection promotes vasodilation by enhancing enos activity through the pi3k/akt signaling pathway in vitro
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054240/
https://www.ncbi.nlm.nih.gov/pubmed/32161546
http://dx.doi.org/10.3389/fphar.2020.00121
work_keys_str_mv AT zhujinqiang shenfuinjectionpromotesvasodilationbyenhancingenosactivitythroughthepi3kaktsignalingpathwayinvitro
AT songwanshan shenfuinjectionpromotesvasodilationbyenhancingenosactivitythroughthepi3kaktsignalingpathwayinvitro
AT xushixin shenfuinjectionpromotesvasodilationbyenhancingenosactivitythroughthepi3kaktsignalingpathwayinvitro
AT mayan shenfuinjectionpromotesvasodilationbyenhancingenosactivitythroughthepi3kaktsignalingpathwayinvitro
AT weibaoyu shenfuinjectionpromotesvasodilationbyenhancingenosactivitythroughthepi3kaktsignalingpathwayinvitro
AT wanghongwu shenfuinjectionpromotesvasodilationbyenhancingenosactivitythroughthepi3kaktsignalingpathwayinvitro
AT huashengyu shenfuinjectionpromotesvasodilationbyenhancingenosactivitythroughthepi3kaktsignalingpathwayinvitro